Autistic neural ‘shiftability’: the distinct pharmacological landscape of the autistic brain

Functionally inter-connected large-scale brain networks regulated by multiple neurotransmitter systems underpin complex human behaviour. A wide range of alterations in this neurofunctional landscape have been associated with autism. However, this evidence is mostly derived from cross-sectional analyses and thus assumes that any differences are ‘static’. Indeed, large sample sizes are required to identify reproducible baseline differences in functional connectivity between autistic and non-autistic individuals. Instead, we propose that what is different in autism is not necessarily the baseline functional connectivity of resting-state networks, but rather their responsivity or regulation by neurotransmitter systems. We tested this hypothesis using a uniform analytical framework to capture the modulation of functional connectivity by single doses of pharmacological probes targeting three major neurotransmitter systems implicated in autism, namely gamma-aminobutyric-acid (GABA), serotonin (5HT) and μ-opioid systems. Every drug challenge altered resting-state network connectivity differentially in the autistic compared to the non-autistic group. However, regardless of the neurotransmitter system probed, drug challenge elicited increases in between-network connectivity in autistic participants but minimal or decreased between-network connectivity in their non-autistic peers. There was no group difference in the responsivity of within-network connectivity. Thus, there is altered responsivity of neurotransmitter systems in the autistic brain. This has important implications for pharmacotherapy in autism because these neurotransmitter systems are the targets of several medications commonly prescribed to manage mental health conditions that frequently co-occur in autism. Investigating if these drug-induced ‘shifts’ in functional connectivity can help provide better targeted clinical interventions will be an important next translational step.

Authors

Institutions

Publication Details

Journal
Translational Psychiatry
Published
2026-08-31
DOI
https://doi.org/10.1038/s41398-026-04371-1
Citations
4
Primary Topic
Autism Spectrum Disorder Research
Type
article
Field-Weighted Citation Impact
6.68

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Autistic neural ‘shiftability’: the distinct pharmacological landscape of the autistic brain

Claire L. Ellis, Robert Wichers, Nichol M. L. Wong, Hester Velthuis et al.
4 citations
Translational Psychiatry
Autism Spectrum Disorder Research
6.68
article

Autistic neural ‘shiftability’: the distinct pharmacological landscape of the autistic brain

Claire L. Ellis, Robert Wichers, Nichol M. L. Wong, Hester Velthuis, Charlotte M. Pretzsch, Lucas G. S. França, Declan Murphy, Gráinne McAlonan, Dafnis Batallé, James L. Findon, Mihail Dimitrov, Tobias P. Whelan, Eileen Daly, Andreia C. Pereira, Johanna Kangas, Nicolaas A.J. Puts, Francesca M. Ponteduro, Naoise Mulcrone
article en
4 citations

Abstract

Functionally inter-connected large-scale brain networks regulated by multiple neurotransmitter systems underpin complex human behaviour. A wide range of alterations in this neurofunctional landscape have been associated with autism. However, this evidence is mostly derived from cross-sectional analyses and thus assumes that any differences are ‘static’. Indeed, large sample sizes are required to identify reproducible baseline differences in functional connectivity between autistic and non-autistic individuals. Instead, we propose that what is different in autism is not necessarily the baseline functional connectivity of resting-state networks, but rather their responsivity or regulation by neurotransmitter systems. We tested this hypothesis using a uniform analytical framework to capture the modulation of functional connectivity by single doses of pharmacological probes targeting three major neurotransmitter systems implicated in autism, namely gamma-aminobutyric-acid (GABA), serotonin (5HT) and μ-opioid systems. Every drug challenge altered resting-state network connectivity differentially in the autistic compared to the non-autistic group. However, regardless of the neurotransmitter system probed, drug challenge elicited increases in between-network connectivity in autistic participants but minimal or decreased between-network connectivity in their non-autistic peers. There was no group difference in the responsivity of within-network connectivity. Thus, there is altered responsivity of neurotransmitter systems in the autistic brain. This has important implications for pharmacotherapy in autism because these neurotransmitter systems are the targets of several medications commonly prescribed to manage mental health conditions that frequently co-occur in autism. Investigating if these drug-induced ‘shifts’ in functional connectivity can help provide better targeted clinical interventions will be an important next translational step.

Translational Psychiatry
King's College London (GB), South London and Maudsley NHS Foundation Trust (GB), Northumbria University (GB), Education University of Hong Kong (HK), Amsterdam Neuroscience (NL), MRC Centre for Neurodevelopmental Disorders (GB), University of Coimbra (PT)
South London and Maudsley NHS Foundation Trust, GW Pharmaceuticals, National Institute for Health and Care Research, Department of Health and Social Care, King's College London, Medical Research Council Centre for Neurodevelopmental Disorders, Greenwich Biosciences, Medical Research Council
Good health and well-being
Openalex Percentile: Top 8%
Autism Spectrum Disorder Research
6.68
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.